MARKET

SLGL

SLGL

SOL GEL TECHNOLG
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.04
-0.13
-1.42%
Closed 16:00 12/03 EST
OPEN
9.24
PREV CLOSE
9.17
HIGH
9.65
LOW
8.99
VOLUME
29.27K
TURNOVER
--
52 WEEK HIGH
21.00
52 WEEK LOW
5.00
MARKET CAP
207.93M
P/E (TTM)
-6.6096
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Sol-Gel Technologies (SLGL) Looks Good: Stock Adds 8.8% in Session
Sol-Gel Technologies (SLGL) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Zacks · 2d ago
What You Need To Know About The Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Analyst Downgrade Today
Market forces rained on the parade of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) shareholders today, when the analysts...
Simply Wall St. · 11/18 05:08
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Just Reported And Analysts Have Been Cutting Their Estimates
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) defied analyst predictions to release its quarterly results, which were ahead...
Simply Wall St. · 11/16 12:25
Recap: Sol-Gel Technologies Q3 Earnings
Shares of Sol-Gel Technologies (NASDAQ:SLGL) moved higher by 0.1% after the company reported Q3 results.Quarterly Results Earnings per share increased 0.00% year over year to ($0.37), which beat the estimate of ($0.46).Revenue of $2,116,000 decreased by 55.29% from the same period last year, which beat the estimate of $1,820,000.Guidance Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Nov 12, 2020View more earnings on SLGLTime: 07:05 AMET Webcast URL: https://www.sol-gel.com/Technicals Company's 52-week high was at $21.00Company's 52-week low was at $5.00Price action over last quarter: Up 15.90%Company Description Sol-Gel Technologies Ltd is a clinical-stage specialty pharmaceutical company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 12, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/12 13:21
The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 11)
Benzinga · 11/12 12:44
Sol-Gel Technologies Q3 EPS $(0.37) Beats $(0.46) Estimate, Sales $2.12M Beat $1.82M Estimate
Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.46) by 19.57 percent. This is unchanged from the same period last year. The company
Benzinga · 11/12 12:16
Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial results for the third quarter ended September 30, 2020 and provided clinical and regulatory updates on its programs.
GlobeNewswire · 11/12 12:08
Sol-Gel Technologies EPS beats by $0.09, beats on revenue
Sol-Gel Technologies (SLGL): Q3 GAAP EPS of -$0.37 beats by $0.09.Revenue of $2.12M (-55.2% Y/Y) beats by $0.3M.Press Release
Seekingalpha · 11/12 12:08
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLGL. Analyze the recent business situations of SOL GEL TECHNOLG through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLGL stock price target is 22.60 with a high estimate of 33.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 36
Institutional Holdings: 8.47M
% Owned: 36.83%
Shares Outstanding: 23.00M
TypeInstitutionsShares
Increased
7
51.32K
New
6
-256.23K
Decreased
6
39.02K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.41%
Pharmaceuticals & Medical Research
+0.49%
Key Executives
Chairman/Director
Moshe Arkin
Chief Executive Officer/Co-Founder/Director
Alon Seri-Levy
Chief Financial Officer
Gilad Mamlok
Vice President - Operations
Itzik Yosef
Vice President
Nissim Bilman
Vice President
Ofra Levy-Hacham
Vice President
Karine Neimann
Vice President
Dov Zamir
Vice President
Dubi Zamir
Vice President - Research & Development
Ofer Toledano
Other
John Vieira
Director
Itai Arkin
Director
Hani Lerman
Independent Director
Shmuel Ben Zvi
Independent Director
Jerrold Gattegno
Independent Director
Ran Gottfried
Independent Director
Yaffa Krindel-Sieradzki
Independent Director
Jonathan Siegel
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SLGL
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Sol Gel Technologies Ltd stock information, including NASDAQ:SLGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLGL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLGL stock methods without spending real money on the virtual paper trading platform.